http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 25 Aug 2026 07:02:59 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Japan+approves+BioCryst%27s+Orladeyo+for+children+ages+2+to+12+with+HAE/26970724.html <p>BioCryst Pharmaceuticals (NASDAQ: BCRX) announced that Japan's Ministry of Health, Labor and Welfare has granted marketing approval for ORLADEYO® (berotralstat) as a once-daily prophylactic therapy for pediatric patients with hereditary angioedema (HAE) aged 2 to under 12 years.</p><p>The approval covers the granule formulation of ORLADEYO, which can be swallowed directly with water or milk, or sprinkled over soft, non-acidic food. The decision is based on interim results from the APeX-P clinical trial, which evaluated pharmacokinetics, safety, and efficacy in 29 patients aged 2 to under 12 years with HAE due to C1-inhibitor deficiency. Interim results showed the drug was generally http://www.streetinsider.com/Corporate+News/Japan+approves+BioCryst%27s+Orladeyo+for+children+ages+2+to+12+with+HAE/26970724.html Tue, 25 Aug 2026 07:02:59 -0400 BCRX http://www.streetinsider.com/FDA/Japan+approves+BioCryst%27s+Orladeyo+for+children+ages+2+to+12+with+HAE/26970724.html <p>BioCryst Pharmaceuticals (NASDAQ: BCRX) announced that Japan's Ministry of Health, Labor and Welfare has granted marketing approval for ORLADEYO® (berotralstat) as a once-daily prophylactic therapy for pediatric patients with hereditary angioedema (HAE) aged 2 to under 12 years.</p><p>The approval covers the granule formulation of ORLADEYO, which can be swallowed directly with water or milk, or sprinkled over soft, non-acidic food. The decision is based on interim results from the APeX-P clinical trial, which evaluated pharmacokinetics, safety, and efficacy in 29 patients aged 2 to under 12 years with HAE due to C1-inhibitor deficiency. Interim results showed the drug was generally http://www.streetinsider.com/FDA/Japan+approves+BioCryst%27s+Orladeyo+for+children+ages+2+to+12+with+HAE/26970724.html Tue, 25 Aug 2026 07:02:59 -0400 BCRX http://www.streetinsider.com/Press+Releases/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html <p align="center"><strong>— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to &lt;12 years in Japan —</strong></p> <p>RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=6yyZZd4cxtntBoyRO3WsLsLpD9R332n57ZcfxtZd526a8HsiDPthHkwvDHVOgnqtq3MKnSg0MXMxwTt_ctNuXw-mWz5A5otqD7ZVukZOMcnHpdJ4lUeBo4EYc4lrMNOD" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has granted marketing approval for once-daily ORLADEYO® (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema (HAE) aged 2 to &lt;12 years.</p> <p align="justify">“The approval of ORLADEYO for children in Japan marks an important step toward our goal of bringing a once-daily oral http://www.streetinsider.com/Press+Releases/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html Tue, 25 Aug 2026 07:01:00 -0400 A.06822034 A.17150087 A.18406154 A.31066700 BCRX O.00165123 O.16087478 O.20026344 O.22422661 O.34929518 http://www.streetinsider.com/Press+Releases/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html <p align="center"><strong>— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to &lt;12 years in Japan —</strong></p> <p>RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=6yyZZd4cxtntBoyRO3WsLsLpD9R332n57ZcfxtZd526a8HsiDPthHkwvDHVOgnqtq3MKnSg0MXMxwTt_ctNuXw-mWz5A5otqD7ZVukZOMcnHpdJ4lUeBo4EYc4lrMNOD" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has granted marketing approval for once-daily ORLADEYO® (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema (HAE) aged 2 to &lt;12 years.</p> <p align="justify">“The approval of ORLADEYO for children in Japan marks an important step toward our goal of bringing a once-daily oral http://www.streetinsider.com/Press+Releases/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html Tue, 25 Aug 2026 07:01:00 -0400 A.06822034 A.17150087 A.18406154 A.31066700 BCRX O.00165123 O.16087478 O.20026344 O.22422661 O.34929518 http://www.streetinsider.com/Press+Releases/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html <p align="center"><strong>— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to &lt;12 years in Japan —</strong></p> <p>RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=6yyZZd4cxtntBoyRO3WsLsLpD9R332n57ZcfxtZd526a8HsiDPthHkwvDHVOgnqtq3MKnSg0MXMxwTt_ctNuXw-mWz5A5otqD7ZVukZOMcnHpdJ4lUeBo4EYc4lrMNOD" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has granted marketing approval for once-daily ORLADEYO® (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema (HAE) aged 2 to &lt;12 years.</p> <p align="justify">“The approval of ORLADEYO for children in Japan marks an important step toward our goal of bringing a once-daily oral http://www.streetinsider.com/Press+Releases/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html Tue, 25 Aug 2026 07:01:00 -0400 A.06822034 A.17150087 A.18406154 A.31066700 BCRX O.00165123 O.16087478 O.20026344 O.22422661 O.34929518 http://www.streetinsider.com/Press+Releases/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html <p align="center"><strong>— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to &lt;12 years in Japan —</strong></p> <p>RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=6yyZZd4cxtntBoyRO3WsLsLpD9R332n57ZcfxtZd526a8HsiDPthHkwvDHVOgnqtq3MKnSg0MXMxwTt_ctNuXw-mWz5A5otqD7ZVukZOMcnHpdJ4lUeBo4EYc4lrMNOD" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has granted marketing approval for once-daily ORLADEYO® (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema (HAE) aged 2 to &lt;12 years.</p> <p align="justify">“The approval of ORLADEYO for children in Japan marks an important step toward our goal of bringing a once-daily oral http://www.streetinsider.com/Press+Releases/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html Tue, 25 Aug 2026 07:01:00 -0400 A.06822034 A.17150087 A.18406154 A.31066700 BCRX O.00165123 O.16087478 O.20026344 O.22422661 O.34929518 http://www.streetinsider.com/Press+Releases/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html <p align="center"><strong>— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to &lt;12 years in Japan —</strong></p> <p>RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=6yyZZd4cxtntBoyRO3WsLsLpD9R332n57ZcfxtZd526a8HsiDPthHkwvDHVOgnqtq3MKnSg0MXMxwTt_ctNuXw-mWz5A5otqD7ZVukZOMcnHpdJ4lUeBo4EYc4lrMNOD" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has granted marketing approval for once-daily ORLADEYO® (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema (HAE) aged 2 to &lt;12 years.</p> <p align="justify">“The approval of ORLADEYO for children in Japan marks an important step toward our goal of bringing a once-daily oral http://www.streetinsider.com/Press+Releases/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html Tue, 25 Aug 2026 07:01:00 -0400 A.06822034 A.17150087 A.18406154 A.31066700 BCRX O.00165123 O.16087478 O.20026344 O.22422661 O.34929518 http://www.streetinsider.com/Press+Releases/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html <p align="center"><strong>— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to &lt;12 years in Japan —</strong></p> <p>RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=6yyZZd4cxtntBoyRO3WsLsLpD9R332n57ZcfxtZd526a8HsiDPthHkwvDHVOgnqtq3MKnSg0MXMxwTt_ctNuXw-mWz5A5otqD7ZVukZOMcnHpdJ4lUeBo4EYc4lrMNOD" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has granted marketing approval for once-daily ORLADEYO® (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema (HAE) aged 2 to &lt;12 years.</p> <p align="justify">“The approval of ORLADEYO for children in Japan marks an important step toward our goal of bringing a once-daily oral http://www.streetinsider.com/Press+Releases/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html Tue, 25 Aug 2026 07:01:00 -0400 A.06822034 A.17150087 A.18406154 A.31066700 BCRX O.00165123 O.16087478 O.20026344 O.22422661 O.34929518 http://www.streetinsider.com/Press+Releases/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html <p align="center"><strong>— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to &lt;12 years in Japan —</strong></p> <p>RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=6yyZZd4cxtntBoyRO3WsLsLpD9R332n57ZcfxtZd526a8HsiDPthHkwvDHVOgnqtq3MKnSg0MXMxwTt_ctNuXw-mWz5A5otqD7ZVukZOMcnHpdJ4lUeBo4EYc4lrMNOD" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has granted marketing approval for once-daily ORLADEYO® (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema (HAE) aged 2 to &lt;12 years.</p> <p align="justify">“The approval of ORLADEYO for children in Japan marks an important step toward our goal of bringing a once-daily oral http://www.streetinsider.com/Press+Releases/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html Tue, 25 Aug 2026 07:01:00 -0400 A.06822034 A.17150087 A.18406154 A.31066700 BCRX O.00165123 O.16087478 O.20026344 O.22422661 O.34929518 http://www.streetinsider.com/Press+Releases/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html <p align="center"><strong>— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to &lt;12 years in Japan —</strong></p> <p>RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=6yyZZd4cxtntBoyRO3WsLsLpD9R332n57ZcfxtZd526a8HsiDPthHkwvDHVOgnqtq3MKnSg0MXMxwTt_ctNuXw-mWz5A5otqD7ZVukZOMcnHpdJ4lUeBo4EYc4lrMNOD" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has granted marketing approval for once-daily ORLADEYO® (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema (HAE) aged 2 to &lt;12 years.</p> <p align="justify">“The approval of ORLADEYO for children in Japan marks an important step toward our goal of bringing a once-daily oral http://www.streetinsider.com/Press+Releases/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html Tue, 25 Aug 2026 07:01:00 -0400 A.06822034 A.17150087 A.18406154 A.31066700 BCRX O.00165123 O.16087478 O.20026344 O.22422661 O.34929518 http://www.streetinsider.com/Press+Releases/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html <p align="center"><strong>— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to &lt;12 years in Japan —</strong></p> <p>RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=6yyZZd4cxtntBoyRO3WsLsLpD9R332n57ZcfxtZd526a8HsiDPthHkwvDHVOgnqtq3MKnSg0MXMxwTt_ctNuXw-mWz5A5otqD7ZVukZOMcnHpdJ4lUeBo4EYc4lrMNOD" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has granted marketing approval for once-daily ORLADEYO® (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema (HAE) aged 2 to &lt;12 years.</p> <p align="justify">“The approval of ORLADEYO for children in Japan marks an important step toward our goal of bringing a once-daily oral http://www.streetinsider.com/Press+Releases/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html Tue, 25 Aug 2026 07:01:00 -0400 A.06822034 A.17150087 A.18406154 A.31066700 BCRX O.00165123 O.16087478 O.20026344 O.22422661 O.34929518 http://www.streetinsider.com/Press+Releases/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html <p align="center"><strong>— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to &lt;12 years in Japan —</strong></p> <p>RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=6yyZZd4cxtntBoyRO3WsLsLpD9R332n57ZcfxtZd526a8HsiDPthHkwvDHVOgnqtq3MKnSg0MXMxwTt_ctNuXw-mWz5A5otqD7ZVukZOMcnHpdJ4lUeBo4EYc4lrMNOD" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has granted marketing approval for once-daily ORLADEYO® (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema (HAE) aged 2 to &lt;12 years.</p> <p align="justify">“The approval of ORLADEYO for children in Japan marks an important step toward our goal of bringing a once-daily oral http://www.streetinsider.com/Press+Releases/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html Tue, 25 Aug 2026 07:01:00 -0400 A.06822034 A.17150087 A.18406154 A.31066700 BCRX O.00165123 O.16087478 O.20026344 O.22422661 O.34929518 http://www.streetinsider.com/Globe+Newswire/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html <p align="center"><strong>— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to &lt;12 years in Japan —</strong></p> <p>RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=6yyZZd4cxtntBoyRO3WsLsLpD9R332n57ZcfxtZd526a8HsiDPthHkwvDHVOgnqtq3MKnSg0MXMxwTt_ctNuXw-mWz5A5otqD7ZVukZOMcnHpdJ4lUeBo4EYc4lrMNOD" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has granted marketing approval for once-daily ORLADEYO® (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema (HAE) aged 2 to &lt;12 years.</p> <p align="justify">“The approval of ORLADEYO for children in Japan marks an important step toward our goal of bringing a once-daily oral http://www.streetinsider.com/Globe+Newswire/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html Tue, 25 Aug 2026 07:01:00 -0400 A.06822034 A.17150087 A.18406154 A.31066700 BCRX O.00165123 O.16087478 O.20026344 O.22422661 O.34929518 http://www.streetinsider.com/Globe+Newswire/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html <p align="center"><strong>— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to &lt;12 years in Japan —</strong></p> <p>RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=6yyZZd4cxtntBoyRO3WsLsLpD9R332n57ZcfxtZd526a8HsiDPthHkwvDHVOgnqtq3MKnSg0MXMxwTt_ctNuXw-mWz5A5otqD7ZVukZOMcnHpdJ4lUeBo4EYc4lrMNOD" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has granted marketing approval for once-daily ORLADEYO® (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema (HAE) aged 2 to &lt;12 years.</p> <p align="justify">“The approval of ORLADEYO for children in Japan marks an important step toward our goal of bringing a once-daily oral http://www.streetinsider.com/Globe+Newswire/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html Tue, 25 Aug 2026 07:01:00 -0400 A.06822034 A.17150087 A.18406154 A.31066700 BCRX O.00165123 O.16087478 O.20026344 O.22422661 O.34929518 http://www.streetinsider.com/Globe+Newswire/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html <p align="center"><strong>— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to &lt;12 years in Japan —</strong></p> <p>RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=6yyZZd4cxtntBoyRO3WsLsLpD9R332n57ZcfxtZd526a8HsiDPthHkwvDHVOgnqtq3MKnSg0MXMxwTt_ctNuXw-mWz5A5otqD7ZVukZOMcnHpdJ4lUeBo4EYc4lrMNOD" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has granted marketing approval for once-daily ORLADEYO® (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema (HAE) aged 2 to &lt;12 years.</p> <p align="justify">“The approval of ORLADEYO for children in Japan marks an important step toward our goal of bringing a once-daily oral http://www.streetinsider.com/Globe+Newswire/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html Tue, 25 Aug 2026 07:01:00 -0400 A.06822034 A.17150087 A.18406154 A.31066700 BCRX O.00165123 O.16087478 O.20026344 O.22422661 O.34929518 http://www.streetinsider.com/Globe+Newswire/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html <p align="center"><strong>— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to &lt;12 years in Japan —</strong></p> <p>RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=6yyZZd4cxtntBoyRO3WsLsLpD9R332n57ZcfxtZd526a8HsiDPthHkwvDHVOgnqtq3MKnSg0MXMxwTt_ctNuXw-mWz5A5otqD7ZVukZOMcnHpdJ4lUeBo4EYc4lrMNOD" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has granted marketing approval for once-daily ORLADEYO® (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema (HAE) aged 2 to &lt;12 years.</p> <p align="justify">“The approval of ORLADEYO for children in Japan marks an important step toward our goal of bringing a once-daily oral http://www.streetinsider.com/Globe+Newswire/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html Tue, 25 Aug 2026 07:01:00 -0400 A.06822034 A.17150087 A.18406154 A.31066700 BCRX O.00165123 O.16087478 O.20026344 O.22422661 O.34929518 http://www.streetinsider.com/Globe+Newswire/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html <p align="center"><strong>— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to &lt;12 years in Japan —</strong></p> <p>RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=6yyZZd4cxtntBoyRO3WsLsLpD9R332n57ZcfxtZd526a8HsiDPthHkwvDHVOgnqtq3MKnSg0MXMxwTt_ctNuXw-mWz5A5otqD7ZVukZOMcnHpdJ4lUeBo4EYc4lrMNOD" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has granted marketing approval for once-daily ORLADEYO® (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema (HAE) aged 2 to &lt;12 years.</p> <p align="justify">“The approval of ORLADEYO for children in Japan marks an important step toward our goal of bringing a once-daily oral http://www.streetinsider.com/Globe+Newswire/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html Tue, 25 Aug 2026 07:01:00 -0400 A.06822034 A.17150087 A.18406154 A.31066700 BCRX O.00165123 O.16087478 O.20026344 O.22422661 O.34929518 http://www.streetinsider.com/Globe+Newswire/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html <p align="center"><strong>— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to &lt;12 years in Japan —</strong></p> <p>RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=6yyZZd4cxtntBoyRO3WsLsLpD9R332n57ZcfxtZd526a8HsiDPthHkwvDHVOgnqtq3MKnSg0MXMxwTt_ctNuXw-mWz5A5otqD7ZVukZOMcnHpdJ4lUeBo4EYc4lrMNOD" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has granted marketing approval for once-daily ORLADEYO® (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema (HAE) aged 2 to &lt;12 years.</p> <p align="justify">“The approval of ORLADEYO for children in Japan marks an important step toward our goal of bringing a once-daily oral http://www.streetinsider.com/Globe+Newswire/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html Tue, 25 Aug 2026 07:01:00 -0400 A.06822034 A.17150087 A.18406154 A.31066700 BCRX O.00165123 O.16087478 O.20026344 O.22422661 O.34929518 http://www.streetinsider.com/Globe+Newswire/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html <p align="center"><strong>— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to &lt;12 years in Japan —</strong></p> <p>RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=6yyZZd4cxtntBoyRO3WsLsLpD9R332n57ZcfxtZd526a8HsiDPthHkwvDHVOgnqtq3MKnSg0MXMxwTt_ctNuXw-mWz5A5otqD7ZVukZOMcnHpdJ4lUeBo4EYc4lrMNOD" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has granted marketing approval for once-daily ORLADEYO® (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema (HAE) aged 2 to &lt;12 years.</p> <p align="justify">“The approval of ORLADEYO for children in Japan marks an important step toward our goal of bringing a once-daily oral http://www.streetinsider.com/Globe+Newswire/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html Tue, 25 Aug 2026 07:01:00 -0400 A.06822034 A.17150087 A.18406154 A.31066700 BCRX O.00165123 O.16087478 O.20026344 O.22422661 O.34929518 http://www.streetinsider.com/Globe+Newswire/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html <p align="center"><strong>— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to &lt;12 years in Japan —</strong></p> <p>RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=6yyZZd4cxtntBoyRO3WsLsLpD9R332n57ZcfxtZd526a8HsiDPthHkwvDHVOgnqtq3MKnSg0MXMxwTt_ctNuXw-mWz5A5otqD7ZVukZOMcnHpdJ4lUeBo4EYc4lrMNOD" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has granted marketing approval for once-daily ORLADEYO® (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema (HAE) aged 2 to &lt;12 years.</p> <p align="justify">“The approval of ORLADEYO for children in Japan marks an important step toward our goal of bringing a once-daily oral http://www.streetinsider.com/Globe+Newswire/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html Tue, 25 Aug 2026 07:01:00 -0400 A.06822034 A.17150087 A.18406154 A.31066700 BCRX O.00165123 O.16087478 O.20026344 O.22422661 O.34929518 http://www.streetinsider.com/Globe+Newswire/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html <p align="center"><strong>— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to &lt;12 years in Japan —</strong></p> <p>RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=6yyZZd4cxtntBoyRO3WsLsLpD9R332n57ZcfxtZd526a8HsiDPthHkwvDHVOgnqtq3MKnSg0MXMxwTt_ctNuXw-mWz5A5otqD7ZVukZOMcnHpdJ4lUeBo4EYc4lrMNOD" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has granted marketing approval for once-daily ORLADEYO® (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema (HAE) aged 2 to &lt;12 years.</p> <p align="justify">“The approval of ORLADEYO for children in Japan marks an important step toward our goal of bringing a once-daily oral http://www.streetinsider.com/Globe+Newswire/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html Tue, 25 Aug 2026 07:01:00 -0400 A.06822034 A.17150087 A.18406154 A.31066700 BCRX O.00165123 O.16087478 O.20026344 O.22422661 O.34929518 http://www.streetinsider.com/Globe+Newswire/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html <p align="center"><strong>— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to &lt;12 years in Japan —</strong></p> <p>RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=6yyZZd4cxtntBoyRO3WsLsLpD9R332n57ZcfxtZd526a8HsiDPthHkwvDHVOgnqtq3MKnSg0MXMxwTt_ctNuXw-mWz5A5otqD7ZVukZOMcnHpdJ4lUeBo4EYc4lrMNOD" rel="nofollow" target="_blank">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq: BCRX) today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has granted marketing approval for once-daily ORLADEYO® (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema (HAE) aged 2 to &lt;12 years.</p> <p align="justify">“The approval of ORLADEYO for children in Japan marks an important step toward our goal of bringing a once-daily oral http://www.streetinsider.com/Globe+Newswire/BioCryst+Announces+Approval+of+ORLADEYO%C2%AE+for+Pediatric+HAE+Patients+in+Japan/26970684.html Tue, 25 Aug 2026 07:01:00 -0400 A.06822034 A.17150087 A.18406154 A.31066700 BCRX O.00165123 O.16087478 O.20026344 O.22422661 O.34929518 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BIOCRYST+PHARMACEUTICALS+++++++++++++++Filed+by%3A+RA+CAPITAL+MANAGEMENT%2C+L.P./26932104.html si-local-file:///var/storage/secattach/20260814/26932104.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BIOCRYST+PHARMACEUTICALS+++++++++++++++Filed+by%3A+RA+CAPITAL+MANAGEMENT%2C+L.P./26932104.html Fri, 14 Aug 2026 16:48:00 -0400 BCRX O.00165123 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BIOCRYST+PHARMACEUTICALS+++++++++++++++Filed+by%3A+RA+CAPITAL+MANAGEMENT%2C+L.P./26932104.html si-local-file:///var/storage/secattach/20260814/26932104.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BIOCRYST+PHARMACEUTICALS+++++++++++++++Filed+by%3A+RA+CAPITAL+MANAGEMENT%2C+L.P./26932104.html Fri, 14 Aug 2026 16:48:00 -0400 BCRX O.00165123 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++BIOCRYST+PHARMACEUTICALS+++++++++++++++Filed+by%3A+STATE+STREET+CORP/26888208.html si-local-file:///var/storage/secattach/20260807/26888208.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++BIOCRYST+PHARMACEUTICALS+++++++++++++++Filed+by%3A+STATE+STREET+CORP/26888208.html Fri, 07 Aug 2026 08:56:00 -0400 BCRX O.00165123